ES2159760T3 - Derivados de aril purina y piridopirimidina y de heteroaril purina y piridopirimidina. - Google Patents

Derivados de aril purina y piridopirimidina y de heteroaril purina y piridopirimidina.

Info

Publication number
ES2159760T3
ES2159760T3 ES96934673T ES96934673T ES2159760T3 ES 2159760 T3 ES2159760 T3 ES 2159760T3 ES 96934673 T ES96934673 T ES 96934673T ES 96934673 T ES96934673 T ES 96934673T ES 2159760 T3 ES2159760 T3 ES 2159760T3
Authority
ES
Spain
Prior art keywords
sub
rent
piridopirimidina
purina
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96934673T
Other languages
English (en)
Inventor
Franco Buzzetti
Maria Gabriella Brasca
Antonio Longo
Dario Ballinari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9523242.7A external-priority patent/GB9523242D0/en
Priority claimed from GBGB9524131.1A external-priority patent/GB9524131D0/en
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Application granted granted Critical
Publication of ES2159760T3 publication Critical patent/ES2159760T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28Oxygen atom
    • C07D473/30Oxygen atom attached in position 6, e.g. hypoxanthine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36Sulfur atom
    • C07D473/38Sulfur atom attached in position 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS COMPUESTOS DE PIRIMIDINA CONDENSADA BICICLICA, QUE POSEEN LA FORMULA GENERAL (I), EN LA QUE X ES UB,2}){SUB,N} CERO O 1; A ES UN ANILLO DE IMIDAZOL CONDENSADO EN 4,5, N SUSTITUIDO CON R{SUB,3}, QUE ES HIDROGENO, ALQUILO C{SUB,1} C{SUB,4} O BENCILO, O A ES UN ANILLO DE PIRIDINA CONDENSADO EN LA POSICION 2,3, C UILO C{SUB,1} O NR{SUB,5}R{SUB,6}, EN EL QUE CADA UNO DE LOS R{SUB,5} Y R{SUB,6} SON INDEPENDIENTEMENTE H O ALQUILO C{SUB,1} ES UN ANILLO BICICLICO QUE SE SELECCIONA ENTRE TETRALINA, INDANO Y 2 PENDIENTEMENTE HIDROGENO, ALQUILO C{SUB,1} O, HIDROXI, ALCOXI C{SUB,1} 4} CARBONILO, NITRO, CIANO O CF{SUB,3}; Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS; Y EN LOS QUE CUANDO AL MISMO TIEMPO A ES PIRIDINA Y B ES UN ANILLO DE TETRALINA, R{SUB,4} ES ALQUILO C{SUB,1} ENO, Y X ES COMO SE HA DEFINIDO ANTERIORMENTE, ENTONCES CADA UNO DE R{SUB,1} Y R{SUB,2} ES DISTINTO DE H; Y EN LOS QUE CUANDO AL MISMO TIEMPO A ES IMIDAZOL, X ES - NH (CH{SUB,2}){SUB,N} COMOSE HA DEFINIDO ANTERIORMENTE, Y B ES UN ANILLO DE INDANO SIN SUSTITUIR O SUSTITUIDO CON UNO O MAS DE HALOGENO, HIDROXI, ALCOXI C{SUB,1} NTO DE ALQUILO C{SUB,1}
ES96934673T 1995-11-14 1996-10-14 Derivados de aril purina y piridopirimidina y de heteroaril purina y piridopirimidina. Expired - Lifetime ES2159760T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9523242.7A GB9523242D0 (en) 1995-11-14 1995-11-14 Aryl and heteroaryl purine compounds
GBGB9524131.1A GB9524131D0 (en) 1995-11-24 1995-11-24 Pyrido-pyrimidine compounds as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2159760T3 true ES2159760T3 (es) 2001-10-16

Family

ID=26308112

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96934673T Expired - Lifetime ES2159760T3 (es) 1995-11-14 1996-10-14 Derivados de aril purina y piridopirimidina y de heteroaril purina y piridopirimidina.

Country Status (17)

Country Link
US (1) US5965563A (es)
EP (1) EP0802914B1 (es)
JP (1) JPH10512896A (es)
CN (1) CN1168138A (es)
AR (1) AR004320A1 (es)
AT (1) ATE201873T1 (es)
AU (1) AU7292096A (es)
BR (1) BR9607089A (es)
CA (1) CA2209598C (es)
DE (1) DE69613211T2 (es)
EA (1) EA000072B1 (es)
ES (1) ES2159760T3 (es)
HU (1) HUP9801177A3 (es)
IL (1) IL121090A0 (es)
NO (1) NO973198L (es)
PL (1) PL321296A1 (es)
WO (1) WO1997018212A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
TW321649B (es) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
EP0824525B1 (en) * 1995-04-27 2001-06-13 AstraZeneca AB Quinazoline derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
AU744986B2 (en) * 1997-07-12 2002-03-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
PL198640B1 (pl) 1998-06-19 2008-07-31 Pfizer Prod Inc Związki pirolo[2,3-d]pirymidynowe, środek farmaceutyczny i zastosowanie tych związków
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
EP1192151B1 (en) 1999-07-09 2007-11-07 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
CN100376567C (zh) 1999-11-05 2008-03-26 阿斯特拉曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
EA006227B1 (ru) 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
EA006153B1 (ru) 2000-06-26 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
WO2003053940A1 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
EP1352910A1 (en) * 2002-04-10 2003-10-15 Grünenthal GmbH New analogs of nitrobenzylthioinosine
AU2003276591A1 (en) 2002-11-26 2004-06-18 Pfizer Products Inc. Method of treatment of transplant rejection
MXPA06001758A (es) * 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
JP4932495B2 (ja) * 2004-01-23 2012-05-16 アムゲン インコーポレイテッド 化合物及び使用方法
CA2553433A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
DE602004009166T2 (de) * 2004-06-29 2008-08-21 Grünenthal GmbH Neue Analoga von Nitrobenzylthioinosin
US7652009B2 (en) * 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
US7910595B2 (en) * 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
US8236950B2 (en) * 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
EP2220078B1 (en) * 2007-10-29 2013-05-22 Amgen, Inc Benzomorpholine derivatives and methods of use
HRP20140395T1 (hr) 2008-08-20 2014-06-06 Zoetis Llc SPOJEVI PIROLO[2,3-d]PIRIMIDINA
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
CA2873967A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
ES2686909B1 (es) 2017-03-22 2019-08-16 Consejo Superior Investigacion Compuestos inhibidores de cdc-7 y su uso para el tratamiento de patologias neurologicas
FR3066761B1 (fr) * 2017-05-23 2020-10-30 Centre Nat Rech Scient Nouveaux composes inhibiteurs des canaux ioniques
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB828522A (en) * 1956-11-02 1960-02-17 Geigy Ag J R Purine derivatives and a process for the preparation thereof
US3112192A (en) * 1960-09-19 1963-11-26 Shell Oil Co Preservation of cut flowers
AU575438B2 (en) * 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
DE3529497A1 (de) * 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
WO1990009178A1 (en) * 1989-01-31 1990-08-23 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
DE69230803T2 (de) * 1991-11-25 2000-12-07 Pfizer Inc., New York 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
US5670501A (en) * 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines

Also Published As

Publication number Publication date
ATE201873T1 (de) 2001-06-15
PL321296A1 (en) 1997-12-08
CA2209598A1 (en) 1997-05-22
EA199700107A1 (ru) 1997-12-30
AR004320A1 (es) 1998-11-04
JPH10512896A (ja) 1998-12-08
BR9607089A (pt) 1997-11-11
DE69613211T2 (de) 2001-11-15
CA2209598C (en) 2005-06-07
IL121090A0 (en) 1997-11-20
MX9705010A (es) 1997-10-31
HUP9801177A3 (en) 1998-11-30
CN1168138A (zh) 1997-12-17
NO973198D0 (no) 1997-07-09
US5965563A (en) 1999-10-12
NO973198L (no) 1997-07-09
WO1997018212A1 (en) 1997-05-22
EP0802914B1 (en) 2001-06-06
HUP9801177A2 (hu) 1998-09-28
EA000072B1 (ru) 1998-06-25
EP0802914A1 (en) 1997-10-29
DE69613211D1 (de) 2001-07-12
AU7292096A (en) 1997-06-05

Similar Documents

Publication Publication Date Title
AR004320A1 (es) Nuevos compuestos de pirimidina condensados biciclicos; un procedimiento para su preparacion; composiciones farmaceuticas que los contienen y su usocomo agentes terapeuticos, en particular como inhibidores de la tirosina quinasa.
ES2188666T3 (es) Analogos de la distamicina utilies como agentes antitumorales o antivirales.
ES2083569T3 (es) Nuevos derivados de ariletenileno y procedimiento para su preparacion.
ES2132223T3 (es) Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4.
ES2065691T3 (es) Derivados de quinuclidina.
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
ES2165357T3 (es) Derivados de metileno-oxiindol y procedimiento de elaboracion.
ES2152317T3 (es) Derivados de arilideno y de heteroarilideno oxiindol utilizados como inhibidores de la tirosina quinasa.
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
ES2157366T3 (es) Derivados de pirimidindiona, pirimidintriona, triacindiona como antagonistas de receptores alfa-1-adrenergicos.
ES2151652T3 (es) Derivados de indol como antagonistas del receptor 5ht.
ES2159758T3 (es) Nuevas n-aminoalquilfluorenocarboxamidas; una nueva clase de ligandos especificos a subtipos del receptor de la dopamina.
ES2160596T3 (es) Derivados de quinuclidina como antagonistas de la sustancia p.
ES2184772T3 (es) Derivados de bifenilo, procedimiento para su preparacion y su utilizacion como medicamentos.
ES2188584T3 (es) Derivados heterociclicos de amina.
ES2181902T3 (es) Derivados de 4,5-diaril-oxazol.
ES2153907T3 (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
ES2191870T3 (es) Pirazoles parasiticidas.
ES2159749T3 (es) Derivados de bencilamino-2-metil-propanamidas 2-(4-sustituidas).
ES2183866T3 (es) Derivados de beta-aril y beta-heteroaril-alfa-cianoacrilamidas sustituido como inhibidors de la tirosina quinasa.
ES2106616T3 (es) Derivados de 11,21-bisfenilo-19-nor-pregnanos.
ES2159922T3 (es) Nuevos derivados de bencimidazol, de benzoxazol y de benzotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2166470T3 (es) Derivados de indolalquilo de la benzodioxanmetilamina como ligandos de los receptores 5-ht1a.
ES2084996T3 (es) Piperazinas sustituidas utiles como agentes para el sistema nervioso central.
ES2123873T3 (es) Pirrolocarbazol.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 802914

Country of ref document: ES